PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry – FDA

Опубликовано 3 октября, 201817 декабря, 2018 frozencat

Обновление руководства FDA:

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry

Руководство замещает Adaptive Design Clinical Trials for Drugs and Biologics – 2010.

Рубрики: Блог

Навигация по записям

Предыдущая запись: Определение объема выборки для исследований биоэквивалентности с использованием компьютерного моделирования
Следующая запись: Работа с данными в IBM SPSS: присвоение меток переменным из другого источника

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

IMG-20170806-WA0006
DJI 0014
20170801 231220
20180814 175743
20180814 180918
20180814 153419
  • CDER Leadership Bios
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-03 By FDA
  • Activities Report of the Generic Drug Program | FDARA Title VIII Sections 807 and 805
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-03 By FDA
  • Improving Anaphylaxis Outcomes: Approaches for Enhancing Access to Epinephrine - 12/16/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-03 By FDA
  • Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 20 mEq Potassium Chloride Injection Due To Overwrap Mislabeled As 10 mEq Potassium Chloride Injection
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-03 By FDA
  • FDA approves 1st drug for thymidine kinase 2 deficiency, a very rare mitochondrial disease
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-03 By FDA
  • Notable Approvals | Drugs
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-03 By FDA
  • Human medicines European public assessment report (EPAR): Mekinist, trametinib, Date of authorisation: 30/06/2014, Revision: 37, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-03
  • Human medicines European public assessment report (EPAR): Spexotras, trametinib, Date of authorisation: 05/01/2024, Revision: 9, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-03
  • Human medicines European public assessment report (EPAR): Atectura Breezhaler, indacaterol,mometasone, Date of authorisation: 30/05/2020, Revision: 13, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-03
  • Human medicines European public assessment report (EPAR): Xromi, hydroxycarbamide, Date of authorisation: 01/07/2019, Revision: 12, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-03
  • Human medicines European public assessment report (EPAR): Myalepta, metreleptin, Date of authorisation: 30/07/2018, Revision: 15, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-03
  • Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab, Date of authorisation: 19/04/2024, Revision: 13, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-03
  • Advisory Letters
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-03 By FDA
  • Quit Kit, LLC - Online Advisory Letter
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-03 By FDA
  • BsUFA IV: Fiscal Years 2028-2032
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-03 By FDA
Предыдущие записи
Тема: Scaffold от Danny Cooper.